Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study.

[1]  A. Lees,et al.  The contribution of amphetamine metabolites of (−)-deprenyl to its antiparkinsonian properties , 2005, Journal of Neural Transmission.

[2]  R. Wise,et al.  Bromocriptine self-administration and bromocriptine-reinstatement of cocaine-trained and heroin-trained lever pressing in rats , 2005, Psychopharmacology.

[3]  G. Manoharan,et al.  Syncopal episodes in a young amateur body builder , 2002, British journal of sports medicine.

[4]  D. Deleu.  Smoking, alcohol, and coffee consumption preceding Parkinson’s disease , 2001, Neurology.

[5]  K. Berridge,et al.  Incentive-sensitization and addiction. , 2001, Addiction.

[6]  D. Schaid,et al.  Smoking, alcohol, and coffee consumption preceding Parkinson’s disease , 2000, Neurology.

[7]  M G Gelder,et al.  Stigmatisation of people with mental illnesses. , 2000, The British journal of psychiatry : the journal of mental science.

[8]  A. Lees,et al.  Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies , 2000, Journal of neurology, neurosurgery, and psychiatry.

[9]  E. Noble,et al.  Addiction and its reward process through polymorphisms of the D2 dopamine receptor gene: a review , 2000, European Psychiatry.

[10]  S. Batki,et al.  Stimulant psychosis: symptom profile and acute clinical course. , 2000, The American journal on addictions.

[11]  M. Farrell,et al.  The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. , 1998, Addiction.

[12]  A. Lang,et al.  Parkinson's disease. Second of two parts. , 1998, The New England journal of medicine.

[13]  G F Koob,et al.  Drug abuse: hedonic homeostatic dysregulation. , 1997, Science.

[14]  J. Fountain,et al.  Adverse effects of stimulant drugs in a community sample of drug users. , 1997, Drug and alcohol dependence.

[15]  J. Nutt,et al.  Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease , 1995, Neurology.

[16]  J. Fermanian,et al.  Mini-Mental Parkinson: first validation study of a new bedside test constructed for Parkinson's disease. , 1995, Behavioural neurology.

[17]  Wade K. Smith,et al.  Midbrain dopaminergic cell loss in parkinson's disease: Computer visualization , 1989, Annals of neurology.

[18]  C. Marsden,et al.  Mood swings associated with the ‘on—off’ phenomenon in Parkinson's disease , 1987, Psychological Medicine.

[19]  J. Ginos,et al.  Intravenous self-administration of dopamine receptor agonists by rhesus monkeys. , 1984, The Journal of pharmacology and experimental therapeutics.